Showing results (101-110 of 137) with videos related to

Sort By:
Pageof 14
Cancers|December 11, 2019
EPSILoN: A Prognostic Score for Immunotherapy in Advanced Non-Small-Cell Lung Cancer: A Validation CohortArsela Prelaj, Roberto Ferrara, Sara Elena Rebuzzi, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 7, 2018
Italian Nivolumab Expanded Access Program in Nonsquamous Non-Small Cell Lung Cancer Patients: Results in Never-Smokers and EGFR-Mutant PatientsMarina Chiara Garassino, Alain Jonathan Gelibter, Francesco Grossi, et al.
Lancet (London, England)|August 9, 2025
Adagrasib versus docetaxel in KRASG12C-mutated non-small-cell lung cancer (KRYSTAL-12): a randomised, open-label, phase 3 trialFabrice Barlesi, Wenxiu Yao, Michaël Duruisseaux, et al.
Clinical Lung Cancer|August 10, 2022
Circulating Fatty Acid Profile as a Biomarker for Immunotherapy in Advanced Non-Small Cell Lung CancerGiulia Galli, Paola Antonia Corsetto, Claudia Proto, et al.
The Oncologist|October 5, 2023
Prognostic Impact of Blood Lipid Profile in Patients With Advanced Solid Tumors Treated With Immune Checkpoint Inhibitors: A Multicenter Cohort StudyFederica Pecci, Luca Cantini, Valeria Cognigni, et al.
Clinical Lung Cancer|August 2, 2021
Immune-Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer With Uncommon HistologySara Manglaviti, Marta Brambilla, Diego Signorelli, et al.
Cancers|January 21, 2022
Machine Learning Using Real-World and Translational Data to Improve Treatment Selection for NSCLC Patients Treated with ImmunotherapyArsela Prelaj, Mattia Boeri, Alessandro Robuschi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 13, 2018
Antibody-Fc/FcR Interaction on Macrophages as a Mechanism for Hyperprogressive Disease in Non-small Cell Lung Cancer Subsequent to PD-1/PD-L1 BlockadeGiuseppe Lo Russo, Massimo Moro, Michele Sommariva, et al.
The Lancet. Oncology|April 2, 2026
Fulzerasib plus cetuximab in first-line KRASG12C-mutated non-small-cell lung cancer (KROCUS): a single-arm, multicentre, phase 1b/2 trialVanesa Gregorc, Margarita Majem, Giuseppe Lo Russo, et al.
Lung Cancer (Amsterdam, Netherlands)|November 2, 2023
High bone tumor burden to identify advanced non-small cell lung cancer patients with survival benefit upon bone targeted agents and immune checkpoint inhibitorsSara Manglaviti, Marta Bini, Giulia Apollonio, et al.
Pageof 14